Navigation Links
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Date:9/10/2009

found that LEVADEX also was effective compared to placebo in treating migraine:

  • in patients with or without allodynia;
  • at any time during the migraine attack, regardless of how long patients had waited to treat a migraine;
  • that occurs in the early morning, also known as "morning migraine";
  • in severely disabled and non disabled patients, as defined by a HIT-6 score;
  • with severe as well as moderate intensity of baseline pain;
  • with severe intensity of pain, providing pain relief at 10 minutes; and
  • with and without nausea, vomiting and aura.

Additional LEVADEX data from the Phase 3 trial showed rapid and sustained efficacy in treating migraine with:

  • pain relief at 10 minutes (p=0.16) and time to pain relief at 30 minutes (p=0.03);
  • sustained pain relief from two to 24 hours in 44 percent of patients compared to 20 percent for placebo (p<0.0001);
  • sustained pain relief from two to 48 hours in 36 percent of patients compared to 17 percent for placebo (p<0.0001, unadjusted for multiplicity); and
  • sustained pain free from two to 24 hours in 23 percent of patients compared to 7 percent for placebo, and from two to 48 hours in 18 percent of patients compared to 6 percent for placebo (p<0.0001 for both timepoints, unadjusted for multiplicity).

There were no drug-related serious adverse events reported in the trial. LEVADEX was well tolerated, with the most common adverse event reported being medication aftertaste at six percent, with two percent of patients receiving placebo also reporting medication aftertaste. The next most common adverse event was nausea at five percent, compared with two percent for placebo. Symptoms or sensitivities typically associated with commonly used triptan migraine treatments, such as ch
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... , Sept. 4, 2015  Cumberland Pharmaceuticals (CPIX), today ... present live at VirtualInvestorConferences.com on September 10, 2015. ... ET LINK: http://tinyurl.com/sep10pre ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:9/4/2015)... DUBLIN , Sept. 4, 2015  Allergan plc (NYSE: ... that Brent Saunders , CEO and President of Allergan, ... at the Morgan Stanley Global Healthcare Conference 2015 in ... http://photos.prnewswire.com/prnh/20150612/222796LOGO The presentation will take ... Time at the Grand Hyatt New York, 109 East 42nd ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com September 10 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3
... STXS ) today announced that executive management will ... Tuesday, September 28, 2010 at 8:30 a.m. ET in New ... of the Company,s business strategy and recent corporate developments. ... A live audio and slides webcast of Stereotaxis, presentation may ...
... Instrumentation Laboratory (IL), today announced it will host the ... 2010 at the Grand Hyatt Nusa Dua, in Bali, Indonesia. ... local time.  The forum will focus on the latest clinical ... practicing in the Asia Pacific region are welcome to attend. ...
Cached Medicine Technology:Stereotaxis to Present at the JMP Securities Healthcare Conference 2Stereotaxis to Present at the JMP Securities Healthcare Conference 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 2Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 4
(Date:9/4/2015)... , ... September 04, 2015 , ... The USC Eye ... ranked number 9 nationwide by Doximity. Faculty, residents and staff are honored to ... pride in the quality of our ophthalmology residency program. Our faculty places a high ...
(Date:9/4/2015)... ... 2015 , ... Having access to a doctor can sometimes be a challenge ... unnecessary emergency room visits which affects hospitals’ abilities to provide quality service to those ... solution to alleviate this problem has recently presented itself, the new telemedicine platform and ...
(Date:9/4/2015)... ... September 04, 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher in ... in the men’s 400 meters final, with an impressive 44.89 seconds at the 2015 ... Jose, Costa Rica in August 2015. The 44.64 time is a new NACAC Championship ...
(Date:9/4/2015)... ... September 04, 2015 , ... Compliance officers deal with ... the Stark physician self-referral law. “Stark Law DOs and DON’Ts: Best Practices ... Services, Inc. (AIS), will detail which deals are attracting the most government scrutiny ...
(Date:9/4/2015)... ... September 04, 2015 , ... FiltersFast.com, the online retail ... cannot be passed up. FiltersFast.com, will ship all orders over $50.00 for ... product replacements. Take advantage of this promotion now through September 8, 2015. , ...
Breaking Medicine News(10 mins):Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2
... Vermont have uncovered the possible causes for brain disorders ... were// published November 1, 2006 in the prestigious journal ... for signaling regional blood flow changes in the brain. ... uninterrupted supply of oxygen and glucose, which is provided ...
... alcohol heavily over a short period of time or drink ... to face more depression than men, says a study.// ... Of Medicine and Health Sciences and other researchers studied the ... history of depression, according to the online edition of BBC ...
... Scientists have now uncovered graphic evidence that suggests a ... occurrence of herpes simplex infection//. The journal, Neurobiology of ... older individuals, the same gene is implicated in causing ... interest to the scientific world. It raises the possibility ...
... A compound derived from the bark of a tree could help ... new study.// ,The new molecule tazopsine was isolated ... science portal SciDev Net. ,Madagascar is an island ... It is the fourth largest island in the world and is ...
... before and for 24 hours after stent placement or ... any significant// treatment effect compared to placebo, according to ... had shown promise in preliminary studies. ,Acute ST-elevation ... following a heart attack) is a major public health ...
... issue of the Journal of the National Cancer Institute, the ... 2005 was $2.3// billion in the first year after diagnosis. ... of cancer care, but few have attempted to include a ... traveling to and from care, waiting for appointments, and receiving ...
Cached Medicine News:Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 2Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 3Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 4Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 2Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 3Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 4Health News:Drug Therapy Offers Little Benefit for Some Patients Undergoing Angioplasty or Stent Procedure 2Health News:Cancer Care-Patient's Time Costs Studied 2
... the M3 and M4 monitors offer wireless ... care. M Series monitors are equipped with ... set of non-invasive parameters and input for ... extensions offer Mainstream or Microstream® CO 2 ...
Compact networked patient monitors for flexible care....
... on Philips strong heritage in patient monitoring, ... extensive clinical measurements menu; built-in clinical support ... 12-lead ECG, and arrhythmia analysis; and many ... to use and operates on a networked ...
... expands hospital-grade monitoring capabilities into the growing ... disease state management. The system is ... full range of clinical applications, from continuous ... to periodic monitoring of patients outside the ...
Medicine Products: